Granules India: Why Emkay Global sees 29% upside in this ‘High-Conviction’ small-cap pick
Emkay Global rates Granules India as ‘Buy’ with a target price of Rs 800, citing its success in the US market and new growth opportunities. Strategic transitions and acquisition in the peptide market are expected to boost margins. Despite regulatory challenges, the company has shown resilience and is expected to see a strong EPS CAGR of 20-25%.